[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhao Jun\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100611584","circulating-immune-markers-for-prognostic-evaluation-in-postoperative-lung-cancer-patients-100611584",false,"NCT07242482","Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients","Study on the Clinical Value of Circulating Immune Markers in Prognostic Evaluation of Postoperative Lung Cancer Patients","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Diagnosed with primary non-small cell lung cancer (NSCLC) and scheduled to undergo curative lung resection at the Department of Thoracic Surgery of our institution.\n* Postoperative pathological stage is IB (with tumor size \\>4cm or high-risk factors: poor differentiation, vascular invasion, visceral pleural invasion, sub-lobar resection, etc.), IIA, IIB, or IIIB (according to the AJCC 8th edition).\n* ECOG performance status of 0 or 1.\n* Voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n* Received any neoadjuvant therapy prior to surgery.\n* History of other active malignancies.\n* Diagnosed with severe autoimmune diseases, active infections, or immunodeficiency disorders.\n* Presence of severe cardiac, hepatic, or renal dysfunction.\n* Pregnant or lactating women.","ALL","18 Years","80 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.",[25,26],"Lung Cancer (Diagnosis)","Biomarkers \u002F Blood",[28,29,30,31],"Peripheral Blood","Tumor antigen specific T cells","Teff\u002FTreg ratio","Prognostic Evaluation","NOT_YET_RECRUITING","2025-11-17",{"date":35,"type":36},"2025-11-21","ACTUAL",{"date":38,"type":21},"2025-12-17",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"Zhao Jun","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100596600","multi-omics-detection-techniques-for-differentiating-benign-and-malignant-pulmonary-nodules-100596600","NCT07047573","Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules","Clinical Application Research on Differentiating Benign and Malignant Pulmonary Nodules Based on Multi-omics Detection Technology","Inclusion Criteria:\n\n* Patient underwent a ct examination\n* Patient was confirmed to have pulmonary nodules\n* Patient has been determined to undergo surgical treatment\n* There are clear pathological results\n* The clinicopathological data are complete\n\nExclusion Criteria:\n\n* Patient has no ct examination results\n* Refuse surgical treatment\n* Patient has no clear pathological diagnosis\n* Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.\n* Patients with tumor emergencies that require immediate treatment.\n* Poor vascular conditions.\n* Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.\n* Patients with hematogenic infectious diseases, such as HBV.\n* Patients with psychiatric disorders or severe mental illnesses.\n* Patients who have difficulty communicating or are unable to be followed up for a long time",true,{"count":54,"type":21},150,"2 Years","Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer",[25,58],"Pulmonary Nodule Persistent",[60,28,29],"Cancer immunotherapy","RECRUITING","2025-06-24",{"date":64,"type":36},"2025-07-02",{"date":66,"type":36},"2025-06-01",{"date":68,"type":21},"2026-06",{"name":42,"class":43},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":44},"100576861","investigating-the-biomarkers-in-tumor-and-peripheral-blood-to-evaluate-the-efficacy-of-cancer-immunotherapy-in-chest-cancer-patients-100576861","NCT06790797","Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","Investigating the Biomarkers in Tumor Microenvironment and Peripheral Blood Microenvironment to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","Inclusion Criteria:\n\n* Patients with a pathological diagnosis of lung cancer or esophageal cancer who have agreed to receive PD-1\u002FPD-L1 antibody immunotherapy;\n* Age between 18 and 80 years old;\n* ECOG PS score of 0 or 1;\n* Adequate organ and bone marrow function;\n* Anticipated survival time of at least 12 weeks;\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.\n* Patients with tumor emergencies that require immediate treatment.\n* Poor vascular conditions.\n* Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.\n* Patients with hematogenic infectious diseases, such as HBV.\n* Patients with psychiatric disorders or severe mental illnesses.\n* Patients who have difficulty communicating or are unable to be followed up for a long time.\n* Other situations that are not suitable for inclusion in the study.",{"count":78,"type":21},50,"This study aims to investigate the impact of immunotherapy on the immune status of tumor microenvironment and peripheral blood of chest cancer patients. To do so, the investigators plan to collect tumor tissue and peripheral blood samples before and after immunotherapy, and use single-cell RNA sequencing, Multiplex immunohistochemistry, and flow cytometry. The investigators will analyze changes in the proportion of cancer cell-specific T-cell subpopulations related to treatment response before and after therapy, and seek biological markers that can predict the efficacy of immunotherapy.",[81,82],"Lung Cancer","Esophageal Cancer",[60,28,84,85,29],"PBMC","T cells","2025-01-18",{"date":88,"type":36},"2025-01-24",{"date":90,"type":36},"2023-02-12",{"date":92,"type":21},"2027-07-30",{"name":42,"class":43},""]